Nautilus Biotechnolgy logo
Nautilus Biotechnolgy
NAUT | NASDAQ
Chart Builder DCF Calculator
$2.10
-$0.22 (-9.48%)
At close: Nov 16, 2026, 4:00 PM ET
$2.13
+$0.03 (+1.37%)
After-hours: Nov 16, 2026, 7:54 PM ET

Nautilus Biotechnolgy Company Profile

Company profile explained

Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Key Executives

Name Position
Sujal Patel Co-Founder, Chief Executive Officer, President, Secretary & Director
Anna Mowry Chief Financial Officer & Treasurer
Gwen E. Weld Chief People Officer
Amber Faust Vice President of Global Sales
Jamie Rose Kuhar Vice President of Marketing
Matthew Murphy ESQ. General Counsel
Parag Mallick Co-Founder, Chief Scientist & Director
Subra Sankar Senior Vice President of Product Development

Latest SEC Filings

Date Type Title
Oct 27, 2026 10-Q Quarterly Report
Oct 27, 2026 8-K Current Report
Sep 18, 2026 EFFECT Filing
Sep 18, 2026 424B5 Filing
Sep 11, 2026 SC 13D/A [Amend] Filing
Sep 11, 2026 8-K Current Report
Sep 11, 2026 S-3 Filing
Aug 28, 2026 SC 13D/A [Amend] Filing
Aug 14, 2026 SC 13D/A [Amend] Filing
Jul 28, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Nautilus Biotechnolgy
Nautilus Biotechnolgy logo
Country United States
IPO Date Aug 7, 2020
Industry Biotechnology
Sector Healthcare
Employees 128
CEO Sujal Patel

Contact Details

2701 Eastlake Avenue East Seattle, Washington 98102 United States

Stock Details

Ticker Symbol NAUT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001808805
CUSIP Number 63909J108
ISIN Number US63909J1088
SIC Code 3826

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.